Gene:
FGB
fibrinogen beta chain

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this . To report a drug label with PGx, click here.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  None
Alternate Symbols:  None
PharmGKB Accession Id: PA163

Details

Cytogenetic Location: chr4 : q31.3 - q31.3
GP mRNA Boundary: chr4 : 155484132 - 155493915
GP Gene Boundary: chr4 : 155474132 - 155496915
Strand: plus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Publications related to FGB: 2

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial. Obstetrics and gynecology. 2008. Johnson Julia V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
-455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen. REGRESS group. Arteriosclerosis, thrombosis, and vascular biology. 1998. de Maat M P, et al. PubMed

LinkOuts

Entrez Gene:
2244
OMIM:
134830
202400
UCSC Genome Browser:
NM_005141
RefSeq RNA:
NM_001184741
NM_005141
RefSeq Protein:
NP_001171670
NP_005132
RefSeq DNA:
AC_000047
AC_000136
NC_000004
NG_008833
NT_016354
NW_001838921
NW_922217
UniProtKB:
FIBB_HUMAN (P02675)
Ensembl:
ENSG00000171564
GenAtlas:
FGB
GeneCard:
FGB
MutDB:
FGB
ALFRED:
LO000204G
HuGE:
FGB
Comparative Toxicogenomics Database:
2244
ModBase:
P02675
HumanCyc Gene:
HS10344
HGNC:
3662

Common Searches